Aelix Therapeutics' Multi-Vector Therapeutic HIV Vaccine Could Be Backbone Of Combination Strategy

Clinical Studies Underway

20 Apr 2021

• By John Davis

Emerging Company Profile: Aelix Therapeutics has constructed a potential therapeutic HIV vaccine to refocus the immune system onto vulnerable parts of the virus, and may allow patients to control viral replication without antiretroviral therapy.

Barcelona, Spain-based AELIX Therapeutics’s proprietary T-cell immunogen has shown a signal of therapeutic benefit in an early clinical study, and the biotech is now aiming to raise series B financing to support further development of the vaccine.

The pharmaceutical/biotech industry has a long history of disappointing attempts to successfully develop HIV prophylactic and therapeutic vaccines, but Aelix...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Immusoft Goes For Cell Therapy Plan ‘B’

26 Feb 2025

• By Alaric DeArment

Emerging Company Profile: CEO Sean Ainsworth spoke with Scrip about how the company is developing B-cell therapies to treat a range of diseases, starting with MPS I.

Sanofi-Backed Resalis Brings MicroRNA To Obesity

29 Nov 2024

• By Elizabeth Cairns

Emerging Company Profile: Resalis will soon start human trials of an oligonucleotide targeting a microRNA that is overexpressed in obese mice, but much remains to be proven in humans.

Volastra Aims To Terminate Cancer Relying On Chromosomal Instability

01 Nov 2024

• By Jessica Merrill

Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.

Seraxis Takes Its Islet Cell Tech Into The Clinic

15 Oct 2024